Regulatory

>

Latest News

FDA Approves Roche’s Evrysdi for Spinal Muscular Atrophy
FDA Approves Roche’s Evrysdi for Spinal Muscular Atrophy

February 13th 2025

Evrysdi is a non-invasive, disease-modifying option that can be swallowed whole or dispersed in water for patients with spinal muscular atrophy.

Navigating the EU’s Joint Clinical Assessment
Navigating the EU’s Joint Clinical Assessment

February 13th 2025

FDA Approves SpringWorks Therapeutics’ Gomekli for Neurofibromatosis Type 1, Symptomatic Plexiform Neurofibromas
FDA Approves SpringWorks Therapeutics’ Gomekli for Neurofibromatosis Type 1, Symptomatic Plexiform Neurofibromas

February 12th 2025

Monica Martin de Bustamante
Changing Political Winds and the IRA: Q&A with Monica Martin de Bustamante

February 12th 2025

More News